title: Clinical amnionitis and endometritis in patients with premature rupture of membranes: endocervical prostaglandin E2 gel versus oxytocin for induction of labor.
abstract: OBJECTIVE
  To compare the rates of clinical amnionitis and endometritis in patients with premature rupture of membranes (PROM), using endocervical prostaglandin E2 (PGE2) gel for induction of labor versus immediate oxytocin induction of labor.
  
  
  METHODS
  We randomized 118 patients to receive either endocervical 0.5 mg of PGE2 gel (study group) or immediate oxytocin induction of labor (control group). If labor was not established in the group receiving PGE2 gel in 24 hours, intravenous oxytocin was given in incremental doses. The rates of clinical amnionitis and endometritis in the two groups were analyzed. Also compared were hours of labor, duration of rupture of membranes and number of vaginal examinations. Student t test, chi 2, or Wilcoxon rank-sum test were used for statistical analysis, as appropriate. P < .05 was considered significant.
  
  
  RESULTS
  The rates of clinical amnionitis were 5.3% in the PGE2 group and 8% in the control group. Endometritis developed in 1.7% of PGE2 patients and 3.2% of controls. These differences in maternal infection rates were not statistically significant. The two groups were comparable with respect to age, parity, and antepartum group B streptococcal colonization. No significant differences in hours of labor, duration of ruptured membranes, or vaginal examinations were observed. Neonatal outcome data (mean birth weight, Apgar scores at 1 and 5 minutes, Apgar score less than 7 at 5 minutes) were not statistically significant.
  
  
  CONCLUSIONS
  Endocervical placement of 0.5 mg of PGE2 gel does not increase the incidence of clinical amnionitis and endometritis in patients with PROM at term when compared with immediate induction of labor with oxytocin.
authors.affiliation: Department of Obstetrics and Gynecology, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA.
authors.forename: N
authors.initials: N
authors.lastname: Malik
authors.forename: L
authors.initials: L
authors.lastname: Gittens
authors.forename: D
authors.initials: D
authors.lastname: Gonzalez
authors.forename: A
authors.initials: A
authors.lastname: Bardeguez
authors.forename: V
authors.initials: V
authors.lastname: Ganesh
authors.forename: J
authors.initials: J
authors.lastname: Apuzzio
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects; D002821:Chorioamnionitis / Q000209:etiology*; D015232:Dinoprostone / Q000008:administration & dosage*; D004716:Endometritis / Q000209:etiology*; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000150:complications*; D005782:Gels; D006801:Humans; D007262:Infusions, Intravenous; D007751:Labor, Induced / Q000009:adverse effects; D010120:Oxytocics / Q000008:administration & dosage*; D010121:Oxytocin / Q000008:administration & dosage*; D011247:Pregnancy; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D005782:Gels; D010120:Oxytocics; D010121:Oxytocin; D015232:Dinoprostone